-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Influenza helps the new crown, should develop influenza—new crown universal vaccine |
Recently, "Cell Research" published an online review article jointly written by Professor Jiang Shibo, Susan and Liu Zezhong at the Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, entitled "Misfortune Does Not Come Single: Influenza Helps New Crowns" "(Double insult: flu bug enhances SARS-CoV-2infectivity), commented on a research paper published by the team of Professor Lan Ke and Xu Ke of the School of Life Sciences of Wuhan University in Cell Research.
The research paper published by the team of Lan Ke and Xu Ke in Cell Research found that the pre-infection of influenza A virus can significantly promote the infectivity of the new coronavirus in a variety of cell types.
Jiang Shibo and others mentioned in the review article that the continuous pandemic of the new crown epidemic and the emergence of new crown virus mutations may cause it to become an epidemic like a seasonal flu.
At present, several multiple vaccines, such as the "diphtheria" multiple vaccine to prevent tetanus, diphtheria and pertussis, and the "mumps" multiple vaccine to prevent measles, mumps and rubella, are in clinical use.
Previously, Jiang Shibo/Lulu’s team had published a research article in the journal Science, proving that the “agonist” cGAMP coated with bionic nanoparticles in the lungs can be used as an adjuvant for the H1N1 influenza vaccine, which can produce H1N1 in animals.
In addition, previous research by the Jiang Shibo/Lulu team also found that a recombinant subunit protein vaccine based on RBD-Fc can induce a highly effective neutralizing antibody response to the new coronavirus and its mutant strains.
Related paper information: org/10.
org/10.
1038/s41422-021-00498-6" target="_blank">https://doi.
org/10.
1038/s41422-021-00498-6